4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Evaxion A/S (EVAX) operates in the Biotechnology industry and is headquartered in Horsholm, Denmark with about 46 employees. Its market capitalization is roughly $28 million. In the fiscal year ended 2025-12-31, EVAX reported $8M in revenue and ($8M) in net income.
Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.
Interactive charts & full statements → Open the EVAX valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Total Revenue | $8M | $3M | $0M | $0M |
| Operating Income (EBIT) | ($9M) | ($15M) | ($22M) | ($25M) |
| Net Income | ($8M) | ($11M) | ($22M) | ($23M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|---|
| Total Revenue | $0M | $0M | $0M | $8M | $0M |
| Operating Income (EBIT) | ($4M) | ($4M) | ($4M) | $3M | ($4M) |
| Net Income | ($4M) | ($4M) | ($6M) | $5M | ($5M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | $28M | $12M | $13M | $22M | — |
| Total Liabilities | $11M | $14M | $18M | $14M | — |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive EVAX viewer.
About TickerBase · Data methodology & sources · Privacy · Terms